HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintained a price target of $19.
June 17, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Cogent Biosciences (NASDAQ:COGT) and maintained a price target of $19.
The reiteration of a Buy rating and the maintenance of a $19 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100